Dizhe Pharmaceutical (688192): The loss reduction in 2024 meets expectations, Globalization benefits are imminent.

It is anticipated that the net loss attributable to the parent company after deducting non-recurring gains and losses in 2024 will be 0.91 billion yuan, which aligns with our expectations. The company has released a performance announcement for 2024: the company's revenue will be 0.36 billion yuan, representing an approximate year-on-year increase of 295%, according to the company.

China International Capital CorporationFeb 25 18:52

Digel Pharmaceuticals: Digel Pharmaceuticals: 2024 Annual Results Express Announcement

SZSIFeb 25 00:00 · Announcements

Dizhe Pharmaceutical: 2024 Annual Results Express Announcement

SZSIFeb 25 00:00 · Announcements

Dizhe Pharmaceutical's Refinancing has been approved by the Securities Regulatory Commission, with 1.85 billion yuan accelerating product research and development and creating an international standard full-chain industrial system.

Shanghai, February 7, 2025 /PRNewswire/ -- On February 7, 2025, Dige Pharmaceutical announced that its Private Placement plan for the Star has been registered with the China Securities Regulatory Commission (hereinafter referred to as "CSRC"). It is expected to raise no more than 1.85 billion yuan, accelerating the research and development progress of core products, while establishing an independent research and production base to complete the full Industry Chain covering the Global discovery, late-stage development, commercialization, production, and sales of Innovative Drugs. This Private Placement plan was announced following the CSRC's "Eight Measures for Deepening the Reform of the Star, Serving Technological Innovation and New Productive Forces Development."

PR NewswireFeb 7 18:08

Dizhe Pharmaceutical (688192.SH): The application for private placement has been approved by the CSRC for registration.

Glonghui, February 7th丨Dizhe Pharmaceutical (688192.SH) announced that the company recently received the "Approval from the China Securities Regulatory Commission regarding the registration of stock issuance by Dizhe (Jiangsu) Pharmaceutical Co., Ltd. to specific targets" (CSRC License [2025] No. 171) (hereinafter referred to as the "Approval Document"). The content of the Approval Document is as follows: 1. The application for stock issuance by your company to specific targets is approved. 2. Your company's issuance must be strictly implemented in accordance with the application documents submitted to the Shanghai Exchange and the issuance plan. 3. This approval is valid for 12 months from the date of registration approval. 4.

Gelonghui FinanceFeb 7 17:57

Dizhe Medicine (688192): The Dihang small molecule track reaches the pinnacle of Global innovation.

Adhere to original innovation, focusing on global competition in the small molecule track: Dizhe Pharmaceuticals is committed to developing Global Innovative Drugs that have a differentiated competitive advantage, maintaining original innovation, and focusing on the discovery of new targets and the verification of action mechanisms. Currently, the company has 6 pipelines under research.

SoochowJan 27 07:37